|
J&J’s HFrEF Expansion | Edwards’ AR Acquisition
August 22, 2024
|
|
|
|
|
Together with
|
|
|
|
“Why is atherosclerotic cardiovascular disease so deadly despite the existence of effective treatments? . . . Millions of individuals with this disease are likely unaware of it.”
|
|
Longevity guru Peter Attia MD.
|
|
|
|
Johnson & Johnson expanded deeper into heart failure and interventional cardiology, acquiring interatrial shunt-maker V-Wave for $600M upfront and up to $1.7B with certain milestones.
- V-Wave’s Ventura Interatrial Shunt is intended to treat HFrEF patients, creating a shunt between the left and right atrium to decrease left atrial pressure.
- V-Wave will become part of J&J MedTech’s cardiovascular portfolio, home to a growing list of recently acquired cardiovascular device businesses.
- The two companies are already well-acquainted, as J&J led V-Wave’s 2016 Series B and was involved in subsequent rounds.
The V-Wave Ventura Interatrial Shunt’s unique approach appears to be quite effective, as a recent study showed a 45% reduction in cardiovascular events and 52% fewer HF hospitalizations over two years, without any procedure-related major adverse events.
- These improvements would allow the Ventura IAS to address the notable HFrEF treatment gap between GDMT and far more invasive therapies like LVAD and heart transplantation.
- The Ventura already has a European CE Mark, and gained FDA Breakthrough Device Designation back in 2019, although its still working towards FDA approval.
- An estimated 800k U.S. patients fall within this HFrEF treatment gap each year, most of whom would be candidates for the Ventura shunt if/when it becomes available stateside.
V-Wave’s attractive interventional heart failure niche and upcoming FDA decision apparently drove this acquisition, noting the growth potential that J&J’s sees in the interventional HFrEF arena and the medtech giant’s ability to bring a first-in-class product like this to market.
In fact, J&J Medtech has aggressively acquired its way towards becoming one of the more diversified cardiotech companies, giving it leadership in EP ablation (Biosense Webster), heart recovery (Abiomed), and intravascular lithotripsy (Shockwave), while adding promising future options for left atrial appendage elimination (Larimar) and now HFrEF (V-Wave).
The Takeaway
Although V-Wave’s Ventura Interatrial Shunt hasn’t proven its market potential, if it truly does become the go-to option for 800k U.S. HFrEF patients, it would be a huge addition to J&J MedTech’s growing (and increasingly impressive) cardiovascular portfolio.
|
|
|
A Single Cardiac Service Line Platform
Transitioning across multiple imaging platforms is a daily reality for many cardiologists, but it doesn’t have to be. See how three leading cardiac imagers are leveraging Circle CVI’s unified multi-modal software across their diverse caseloads, without switching to other platforms.
|
|
Monebo’s Customers Lead the Way
Monebo’s customers span across the globe, and range from local cardiac monitoring companies to major ECG OEMs. See what they all have in common, and how the Monebo monitoring advantage might help your business.
|
|
The Bunkerhill Blueprint
Advancing an AI solution from concept to clinic used to take years, but Bunkerhill Health is closing that gap at lightning speed. See how Bunkerhill is streamlining AI training, validation, approval, and commercialization to get better AI tools into clinical practice, faster.
|
|
- Ezetimibe + Statin Advantage: A meta-analysis found that adding ezetimibe to low/moderate-intensity statins lowered LDL-C levels in ASCVD patients more effectively than high-intensity statins alone (average difference: -6.6 mg/dL). This didn’t lead to a reduction in MACE, but the combo group did have fewer cases of myalgia (73% lower risk) and far fewer therapy discontinuations due to adverse events (40% lower risk).
- Edwards Acquires JC Medical: Edwards Lifesciences’ continued its acquisition spree, buying aortic valve-maker JC Medical from Genesis MedTech for an undisclosed sum, while making a $25M investment in Genesis. The acquisition gives Edwards the IP and commercial rights for JC Medical’s J-Valve System, a transcatheter aortic valve for treating severe aortic regurgitation, while Genesis maintains J-Valve’s rights in China. Since selling its Critical Care business for $4.2B, Edwards has also acquired JenaValve (TAVR for AS & AR), Endotronix (implantable HF monitor), Innovalve Bio (TMVR), and Affluent Medical (surgical mitral valve).
- Echo AI’s MR Potential: Echo AI might help address challenges with mitral regurgitation assessment quality and efficiency. Researchers in JACC: Cardiovascular Imaging used Us2.ai’s echo AI solution to automatically grade MR severity (in 80 seconds per exam), achieving 0.80 accuracy detecting severe MR and 0.97 accuracy detecting either moderate or severe MR (with 0.96 sensitivity and 0.98 specificity). Moreover, patients with AI-detected severe MR had five-times higher mortality rates at one year compared to mild MR patients.
- Rethinking CCTA Reimbursements: After years of rising volumes and declining payments, CMS is considering doubling CCTA reimbursements from its current $175 rate for both hospital-based and outpatient exams. The reimbursement hike would be made possible by adopting a new cardiology code, noting that CCTAs were previously billed the same as lower-cost chest CTs, making the heart exams unprofitable for many provider organizations.
- Metabolic Syndrome Body Scan: A Mayo Clinic team used Select Research’s white-light 3D-BV body scanner – normally used for fitting clothes – to scan 1.3k people for signs of metabolic syndrome. The scanner detected metabolic syndrome more accurately than traditional metrics like BMI and waist-to-hip ratio, suggesting that 3D-BV scans could someday find a home in healthcare. The images alone are worth checking out.
- HeartMate Goes Aspirin-Free: The ARIES-HM3 trial showed that LVAD patients experience far less bleeding and shorter hospital stays if they cut aspirin from their anticoagulant regimen, with no greater risk of blood clot formation. And after about 10 months, the FDA has approved a change to the HeartMate 3’s label that removes aspirin from the device’s post-implant blood thinning strategy.
- Optimal Therapy Improves HF Outcomes: Data from the CHAMP-HF trial showed that stratifying HFrEF patients according to their optimal medical therapy (OMT) scores could help predict long-term outcomes. The researchers assigned 1-5 OMT scores to 4,582 participants based on GDMT use and HF medication dosing. Unsurprisingly, patients with “optimal” OMT scores had significantly lower rates of all-cause and cardiovascular death compared to those with “acceptable” or “suboptimal” scores.
- Liquidia’s Tentative PAH Approval: The FDA tentatively approved Liquidia’s Yutrepia (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension related to interstitial lung disease. That’s good news in the long term for Liquidia, but disappointing in the short term because they’ll likely have to wait until May 2025 when United Therapeutics’ competing Tyvaso DPI treatment is no longer market-exclusive. Liquidia plans to challenge the FDA’s exclusivity decision and get Yutrepia to market before then.
- Varied Benefit for Verinurad: A phase 2 trial showed that giving HFpEF patients with high serum uric acid (SUA) the new urate-lowering drug verinurad plus allopurinol reduced their SUA levels more than allopurinol alone or a placebo (mean drop: -59.6% vs. -37.6% & +0.8%). However, the combo therapy didn’t translate to an improvement in exercise capacity (peak VO2) or symptoms.
- Lexicon Refocuses: Lexicon Pharmaceuticals will lay off half of its current field force as it “right-sizes” its Inpefa marketing for heart failure (sotagliflozin, FDA approved) and “reallocates” resources towards Zynquista’s potential launch for type 1 diabetes and CKD (also sotagliflozin, awaiting FDA approval). The cuts also ensure funding for Lexicon’s Phase 3 study evaluating sotagliflozin in HCM and its Phase 2b study of LX9211 for diabetic neuropathic pain. Inpefa will now follow a more “targeted approach” for HF.
- Machine Learning Flags FH: An ML algorithm looks promising for identifying people with familial hypercholesterolemia and treating them with guideline-directed therapies. In a retrospective study of records from 2.1 million patients treated at a university health system and not diagnosed with FH, the FIND FH algorithm flagged 471 (.4%) for review. Of those flagged patients, 32 had established FH, 121 had likely HF, and 318 were highly suspected. The findings were consistent with other studies using the ML algorithm.
|
|
The Post-Acute Stroke Game Changer
See how Viz Connect solution can optimize your post-acute stroke pathway. The Viz.ai solution allows the cardiology team to promptly receive Neurology referrals to evaluate patients with suspected AFib for cardiac monitoring and reduce their risk of secondary stroke.
|
|
Tracking Your Post-Treatment Plaque
Tune-in to this on-demand Cleerly webinar where preventative cardiologist John Osborne, MD, PhD, FACC, FNLA explores how to use CTA to track plaque progression and identify residual risk post-treatment.
|
|
Catch up on 2024’s Cardiology Coffee Breaks
Join GE HealthCare on a journey to bridge the gaps to connected cardiovascular care with this season’s Cardiology Coffee Breaks. In the time it takes you to finish your coffee, these Coffee Breaks demonstrate how GE’s integrated solutions empower healthcare organizations to provide precision care, achieve operational efficiency, and enhance patient satisfaction.
|
|
- AI Algorithms in Cardiology: Navigating the Path from Research to Practice: Join Tempus on Tuesday, September 24 for an in-depth webinar exploring the transformative power of cardiology AI algorithms. Learn from leading experts, including Cedars Sinai’s Dr. David Ouyang and Tempus’ senior cardiology team Dr. Brandon Fornwalt and Dr. John Pfeifer, about how cardiology AI algorithms are unlocking new possibilities for diagnosis, treatment, and patient outcomes. Secure your spot now to be part of this pivotal discussion.
- Merge Cardiology is Best in KLAS: Merge Cardio and Merge Hemo continued their KLAS hot streak, ranking Best in KLAS 2024 for Cardiology and Hemodynamics for the 9th and 12th years. The Merge by Merative cardiology solutions further expanded their KLAS score leads this year, with Merge Cardio scoring 82.8 (up from 82.7 last year) and Merge Hemo surging to 91.5 (from 85.7 in 2023).
- PIA Medical Processes It All: Need an analysis like calcium scoring, strain or even FFR? PIA Medical began as a Core Lab and can handle creative cardiac research and clinical trials along with the full breadth of clinical analyses available today.
- Planning Your Move to The Cloud: There’s a long list of advantages to transitioning your enterprise imaging to the cloud, but you have to plan that move first. This Optum e-book details what health IT and imaging leaders need to know before moving their enterprise medical imaging to the cloud.
- Us2.ai’s Contrast Echo Correlations: Check out what might be the first study evaluating the performance of AI-automated contrast echocardiography exams, which found that Us2.ai’s echo AI solution produced LV measurements with “good to excellent agreement” with human experts.
- Advance Your Cardiac MR Visualization: Ready to advance your CMRI assessments? See how you could leverage TeraRecon’s Intuition Cardiac MR package for a range of cardiac anatomy and physiology evaluations, and how your peers are already benefiting from it.
- Experience the future of learning: Medtronic Academy 2.0 is here! Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
- An All-in-One Coronary Care Solution: See how HeartFlow ONE is transforming precision heart care as the first all-in-one CCTA pathway, combining FFRCT, stenosis, and plaque analysis in a single workflow.
|
|
|
|
|
